AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15755866
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (850 mg/d)
Trial: 7893868
Drug: Ceftazidime (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (120 mg/[kg.d])
Trial: 7893868
Drug: Amoxicillin/clavulanate (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (160 mg/[kg.d])
Trial: 2447403
Drug: epanolol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol, 200 mg b.i.d.
Trial: 2447403
Drug: pindolol, 10
RxNorm normalized name: Pindolol, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol, 10 mg b.i.d.
Trial: 2447403
Drug: epanolol, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol, 400 mg q.d.
Trial: 2447403
Drug: pindolol, 10
RxNorm normalized name: Pindolol, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol, 10 mg b.i.d. and epanolol, 200 mg b.i.d.
Trial: 29608967
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in older patients (65 years and older)
Trial: 29608967
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in younger patients (younger than 65 years)
Trial: 22561596
Drug: Desmopressin (DDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (DDAVP) 0.2 mg orally
Trial: 17991531
Drug: 3-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day standard bowel preparation (group 1)
Trial: 17991531
Drug: Soft diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft diet with no oral intake 8 hours before surgery (group 2)
Trial: 12006190
Drug: 532 nm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for upper lip wrinkles
Trial: 12006190
Drug: 532 nm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for facial acne scarring
Trial: 9893933
Drug: Test 1
RxNorm normalized name: Bar Test 10% Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 1 (chewable tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Trial: 9893933
Drug: Test 2
RxNorm normalized name: Methitest 25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 2 (effervescent tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Trial: 9893933
Drug: Ref1 (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ref1 (tablets containing 76 mg Na2FPO3)
Trial: 9893933
Drug: Ref2 (effervescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ref2 (effervescent tablets containing 76 mg Na2FPO3 and 3240 mg calcium lactogluconate/carbonate)
Trial: 2840815
Drug: Lisinopril 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5.0 mg
Trial: 2840815
Drug: Lisinopril (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (various doses)
Trial: 8018302
Drug: Drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatments to reduce hypertension and hyperlipidaemia
Trial: 368370
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C prophylaxis, 2.0 g/day
Trial: 31794152
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate hydrate (ZAH; 50 mg/day)
Trial: 31794152
Drug: Polaprezinc (PPZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polaprezinc (PPZ; 34 mg/day)
Trial: 27638233
Drug: Deterioration in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st 12 months
Trial: 27638233
Drug: Deterioration in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st year
Trial: 25794285
Drug: Escitalopram (10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10.0 ± 4.0 mg/day)
Trial: 25794285
Drug: Sertraline (78.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (78.6 ± 26.7 mg/day)
Trial: 25794285
Drug: Paroxetine controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine controlled-release formulation (18.8 ± 8.8 mg/day)
Trial: 19557566
Drug: Infrared (IR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared (IR) treatment for 20 minutes
Trial: 19557566
Drug: Therapeutic ultrasound
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic ultrasound (US) treatment for 10 minutes
Trial: 16129844
Drug: G‐CSF schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF schedule 5 (300 microg/d days 8 and 12)
Trial: 16129844
Drug: G‐CSF (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (any schedule)
Trial: 11166906
Drug: vCP205 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vCP205 and SF-2 rgp120 subunit vaccines
Trial: 21158953
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of ascorbic acid (AA)/kg diet
Trial: 12805552
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation of the stimulus at one location
Trial: 7742084
Drug: 1,25(OH)2D3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 treatment
Trial: 2043077
Drug: Antibiotic rinse/storage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic rinse/storage (neomycin‐polymyxin B‐gramicidin)
Trial: 7028312
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and Promethazine combination
Trial: 24126895
Drug: NaHCO3 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (0.3 g·kg(‐1) body mass)
Trial: 24126895
Drug: Placebo (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sodium chloride NaCl: 0.045 g·kg(‐1) body mass)
Trial: 20543025
Drug: Conversation intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversation intervention (500 min of linguistically and cognitively complex talk over 10 weeks, 25 min twice weekly)
Trial: 12028854
Drug: 4 or
RxNorm normalized name: Dex4 Orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 or 8 mg/day of buprenorphine
Trial: 7670648
Drug: ACE-inhibitor (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor (n = 135)
Trial: 7670648
Drug: Calcium-antagonist (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-antagonist (n = 131)
Trial: 7670648
Drug: ACE-inhibitor and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor and Calcium-antagonist
Trial: 2166885
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (NS) 4 mg four times daily
Trial: 2166885
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BD) 0.1 mg four times daily
Trial: 17400089
Drug: PS implants
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS implants designed for increased flexion
Trial: 17400089
Drug: Standard posterior-stabilized
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard posterior-stabilized (PS) implants
Trial: 16350714
Drug: 1alpha‐OHD3 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1alpha‐OHD3 (0.5 microg/d) and calcium carbonate (1 g daily)
Trial: 16350714
Drug: Complete androgenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete androgenic blockade (orchidectomy + flutamide 750 mg daily)
Trial: 1729065
Drug: Amrinone (2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (2.25 mg/kg bolus + 20 micrograms/kg/min)
Trial: 6741156
Drug: Traditional prolonged-action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional prolonged-action theophylline-ethylenediamine preparation
Trial: 31248307
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 10 weeks
Trial: 29224639
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care medication
Trial: 26742777
Drug: Lesinurad 200
RxNorm normalized name: lesinurad 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 200 mg/day in combination with allopurinol
Trial: 26742777
Drug: Lesinurad 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 400 mg/day in combination with allopurinol
Trial: 26742777
Drug: Lesinurad 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 600 mg/day in combination with allopurinol
Trial: 26742777
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with allopurinol
Trial: 14967866
Drug: 8% CHOexo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% CHOexo (1 g glucose x kg x h(‐1))
Trial: 10758775
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Azectol)
Trial: 3040918
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four drugs (VDS, CCNU, CTX, MTX)
Trial: 3040918
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with dose‐limiting toxicity
Trial: 26928185
Drug: Intraoperative periarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative periarticular injection (PAI)
Trial: 10230948
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol infusion (1 mg/kg/h)
Trial: 10230948
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol infusion
Trial: 1524328
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract using cefotaxime (1 g IV every 8 hours for the first 3 days) and oral nonabsorbable antibiotics (gentamicin, polymyxin, and nystatin) for the entire stay in the ICU
Trial: 6231062
Drug: Micronized etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized etodolac in capsule and tablet forms
Trial: 6231062
Drug: Regular etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular etodolac dosage forms
Trial: 6231062
Drug: Etodolac with
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac with antacid (magaldrate)
Trial: 6231062
Drug: Etodolac with
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac with antiulcer agent (sucralfate)
Trial: 6231062
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose or divided (b.i.d.) doses of etodolac in man
Trial: 31697698
Drug: GOAL program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOAL program (twice weekly group sessions for 10 weeks, 20 sessions)
Trial: 27322638
Drug: Blood alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood alcohol concentration (BAC) of approx. 0.5g/L
Trial: 27322638
Drug: Blood alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood alcohol concentration (BAC) of approx. 0.9g/L
Trial: 19255158
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal ranibizumab (0.3 or 0.5 mg)
Trial: 19255158
Drug: Sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injections (control group in MARINA)
Trial: 19255158
Drug: Monthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly ranibizumab (0.3 or 0.5 mg) with sham photodynamic therapy (PDT)
Trial: 19255158
Drug: Sham ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ocular injections with verteporfin PDT (control group in ANCHOR)
Trial: 17720114
Drug: HPbetaCD diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPbetaCD diclofenac sodium 75 mg
Trial: 17720114
Drug: PG‐BA diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG‐BA diclofenac sodium 75 mg
Trial: 12421175
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg orally + Misoprostol 0.4 mg vaginally (Mf + Ms)
Trial: 12421175
Drug: Misoprostol 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 0.4 mg vaginally (Ms)
Trial: 9871426
Drug: Fexofenadine hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride (single doses of 10 to 800 mg)
Trial: 9871426
Drug: Fexofenadine hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride (multiple doses of 20 to 690 mg twice daily for 28 1/2 days)
Trial: 977791
Drug: Chlordesmethyldiazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordesmethyldiazepam (2 mg)
Trial: 977791
Drug: Chlordesmethyldiazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordesmethyldiazepam (1 mg)
Trial: 31220991
Drug: Four-step tapering
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-step tapering (DRESS strategy)
Trial: 31220991
Drug: Five-step tapering
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Five-step tapering
Trial: 31220991
Drug: Tapering without
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering without withdrawal
Trial: 31220991
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of a theoretical predictor for successful tapering
Trial: 31220991
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of treatment
Trial: 21932661
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT), once a day for 6 consecutive days
Trial: 21932661
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, no treatment specified
Trial: 18377145
Drug: Children's medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's medication use
Trial: 12683268
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (preferential indication for clozapine)
Trial: 12683268
Drug: Long-acting depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting depot neuroleptic preparations
Trial: 12683268
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics in acute and long-acting intramuscular forms
Trial: 12683268
Drug: Adjunctive medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive medications
Trial: 8826489
Drug: Topical indomethacin/diethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical indomethacin/diethyl ether mixture
Trial: 8826489
Drug: Topical diclofenac/diethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac/diethyl ether mixture
Trial: 1419008
Drug: Amantadine 1
RxNorm normalized name: amantadine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 1 g orally in divided doses over a period of 25 hours prior to surgery, along with diazepam 5 mg orally 1 hour prior to induction of anesthesia.
Trial: 1419008
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg orally 1 hour prior to induction of anesthesia (Control group).
Trial: 31793646
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements for pregnant and lactating women and children 6-59 months of age
Trial: 28459136
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg grapiprant (oral administration)
Trial: 28459136
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg grapiprant (i.v. administration)
Trial: 24220326
Drug: MenACWY‐CRM with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐CRM with routine vaccines
Trial: 7890057
Drug: Cyclic sodium
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic sodium etidronate and low-dose norethindrone (2.5 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group I)
Trial: 7890057
Drug: Low-dose norethindrone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose norethindrone (10 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group II)
Trial: 31043177
Drug: Rifampicin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin treatment for up to 31 days
Trial: 20383544
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant loading within 1 week after implant insertion
Trial: 20383544
Drug: Conventional loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional loading of palatal implants after a healing period of 12 weeks
Trial: 19448380
Drug: Carbohydrate-rich drink
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich drink (12.5 g carbohydrates/100 ml, pH 5.0) given shortly before surgery
Trial: 11934726
Drug: Prolonged methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged methylprednisolone administration
Trial: 9806049
Drug: Ganciclovir from
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir from engraftment without prior acyclovir treatment (Group 1)
Trial: 9806049
Drug: Ganciclovir at
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir at engraftment with prior intravenous acyclovir (500 mg/m2 every 8 h) (Group 3)
Trial: 347294
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon (two highest dosage levels)
Trial: 31424576
Drug: mFOLFOX6 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 chemotherapy with SIRT (yttrium-90 resin microspheres)
Trial: 31424576
Drug: mFOLFOX6 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 chemotherapy without SIRT (control arm)
Trial: 29336621
Drug: Beta-Alanine (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-Alanine (3.2 g/day)
Trial: 26818850
Drug: Prophylactic amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic amiodarone (5 mg/kg IV loading dose, continuous infusion of 10-15 μg/kg/min for 3 days)
Trial: 22174436
Drug: 1-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g dose of doripenem administered intravenously over 4 hours
Trial: 22174436
Drug: 2-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g dose of doripenem administered intravenously over 4 hours
Trial: 22174436
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg and 1 g doses of doripenem administered over 4 hours in adult healthy volunteers (HVs)
Trial: 16412928
Drug: Gatifloxacin 0.3%
RxNorm normalized name: GATIFLOXACIN 0.3% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 0.3% instilled hourly for 10 hours
Trial: 16412928
Drug: Moxifloxacin 0.5%
RxNorm normalized name: Moxifloxacin 0.5%, Bromfenac 0.075% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 0.5% instilled hourly for 10 hours
Trial: 12441586
Drug: Chicken Soup
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [CHICKEN SOUP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken Soup for the Soul at Work Employee Groups intervention, consisting of nine weekly meetings.
Trial: 7570433
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol 5 mg and ipratropium bromide 500 micrograms (4 times a day)